Concepedia

Author

Franck E. Nicolini

Inserm

Also Known As

F E Nicolini, F Nicolini, F. Nicolini, F.E. Nicolini, Franck E Nicolini, Franck E. Nicolini, Franck Emmanuel Nicolini, Franck Nicolini, Franck- Emmanuel Nicolini, Legros, Laurence

161

Publications

7.7K

Citations

27

H-Index

24

Concepts

All Affiliations

InsermHôpital Saint-LouisInstitut BergoniéHôpital Lyon SudHôpital Edouard Herriot
FE

About

Franck E. Nicolini is an author at Inserm specializing in medicine, hematology, and oncology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

14

15

3.2K

2

Health Sciences

8

8

2.3K

3

Cell Biology

6

6

249

4

Engineering

1

1

28

5

Diagnostic Sciences

1

1

13

Franck E. Nicolini

×

42

Publications

5.3K

Citations

26

H-Index

YearCitations

Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial

François‐Xavier Mahon, Delphine Réa, Joëlle Guilhot,

The Lancet Oncology

2010

1.5K

Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial

Johan Richter, Joëlle Guilhot, Franz Gruber,

The Lancet Oncology

2018

587

Long-Term Follow-Up of the French Stop Imatinib (STIM1) Study in Patients With Chronic Myeloid Leukemia

Gabriel Étienne, Joëlle Guilhot, Delphine Réa,

Journal of Clinical Oncology

2016

484

Chronic myeloid leukemia stem cells are not dependent on Bcr-Abl kinase activity for their survival

Ashley Hamilton, G. Vignir Helgason, Mirle Schemionek,

Blood

2011

421

Loss of Major Molecular Response As a Trigger for Restarting Tyrosine Kinase Inhibitor Therapy in Patients With Chronic-Phase Chronic Myelogenous Leukemia Who Have Stopped Imatinib After Durable Undetectable Disease

Philippe Rousselot, Aude Charbonnier, Pascale Cony‐Makhoul,

Journal of Clinical Oncology

2013

405

Imatinib plus Peginterferon Alfa-2a in Chronic Myeloid Leukemia

Claude Preudhomme, Joëlle Guilhot, Franck E. Nicolini,

New England Journal of Medicine

2010

382

Peripheral artery occlusive disease in chronic phase chronic myeloid leukemia patients treated with nilotinib or imatinib

T D Kim, Delphine Réa, Michaela Schwarz,

Leukemia

2013

233

Natural killer-cell counts are associated with molecular relapse-free survival after imatinib discontinuation in chronic myeloid leukemia: the IMMUNOSTIM study

Delphine Réa, Guylaine Henry, Zena Khaznadar,

Haematologica

2017

147

Report of 34 patients with clonal chromosomal abnormalities in Philadelphia-negative cells during imatinib treatment of Philadelphia-positive chronic myeloid leukemia

Christine Terré, Virginie Éclache, Philippe Rousselot,

Leukemia

2004

139

Second tyrosine kinase inhibitor discontinuation attempt in patients with chronic myeloid leukemia

Laurence Legros, Franck E. Nicolini, Gabriel Étienne,

Cancer

2017

105

Page 1